問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Neurology

Division of Neurology

更新時間：2023-09-19

林俊杰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林俊杰

List

6Cases

2020-09-01 - 2024-03-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-05-01 - 2018-12-03

IIT

Phase III

Completed
Extending the time for Thrombolysis in Emergency Neurological Deficits

  • Condition/Disease

    Acute Ischaemic Stroke

  • Test Drug

    Tissue Plasminogen Activator (tPA)

Participate Sites
9Sites

Suspended8Sites

Study ended1Sites

蔡崇豪
China Medical University Hospital

Division of Neurology

2011-08-01 - 2014-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-03-11 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

2015-04-01 - 2018-12-31

Phase III

Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 or 150 mg, oral, b.i.d) versus acetylsalicytic acid (100mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).

  • Condition/Disease

    Embolic stroke of undetermined source

  • Test Drug

    Pradaxa/Placebo

Participate Sites
14Sites

Terminated13Sites

Study ended1Sites

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB